Home>
Stocks>
Hester Biosciences Ltd

Hester Biosciences Ltd (HESTERBIO)

₹1692.05▲0.28%

Get free price alerts. Set up your Free investment account to get Live Prices. >

Overview

Fundamentals

Q3 '23 Results

Technicals

News and Events

Hester Biosciences Ltd share Performance

₹1675.75
₹1723.3
₹1692.05
0.96%
Low
Day's Volatility:2.81%
High
1.85%
₹1292.85
₹1939.95
₹1692.05
23.59%
Low
52 Weeks Volatility:38.24%
High
14.65%

Returns %
1 Month Return	4.15 %
3 Month Return	17.56 %
1 Year Return	-4.62 %

Market Stats
Previous Close	₹1,696.80
Open	₹1,700.00
Volume	7,037.00
Upper Circuit	-
Lower Circuit	-
Market Cap	₹1,443.44Cr

Company Information

Hester Pharmaceutical (HPL), established as a private limited company in April 1987 and transitioning to a public limited company in November of 1993, offers a range of veterinary and pharmaceutical products, such as animal health products, poultry vaccines, and laboratory kits and reagents. Furthermore, it markets the veterinary products of up to 10 international companies, including Ghen Corporation (Japan), Maine Biological Laboratories (US), Idexx Corporation (US), and Biogal Galed Laboratories (Israel). Entering the production of veterinary vaccines in vials, HPL also has technical collaborations with Maine Biological Laboratories and Ghen Corporation, and has since received licenses for producing an additional 10 poultry vaccines. To facilitate increased production, HPL has signed a manufacturing agreement with Sinsui Inc. for the production of additional poultry vaccines. Overall, HPL has continued to grow in the years since it was first established.

Share Price: ₹1692.05 per share as on 03 May, 2024 04:01 PM
Market Capitalisation: ₹1,443.44Cr as of today
Revenue: ₹66.98Cr as on December 2023 (Q4 23)
Net Profit: ₹4.02Cr as on December 2023 (Q4 23)
Listing date: 13 Mar, 2015

Organisation	Hester Biosciences Ltd
Headquarters
Industry	Pharmaceuticals
E-voting on shares	Click here to vote

Key events for Hester Biosciences Ltd

Sanjay Dalal Steps Down as COO of Hester Biosciences - 29 Feb, 2024
Hester Biosciences' Chief Operating Officer, Sanjay Dalal, has stepped down from his role effective February 29, 2024. Dr. Ram Prakash will assume the position starting March 1, 2024.

Fundamentals of Hester Biosciences Ltd

Insights on Hester Biosciences Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

NO EFFECT
Retail Holding Unchanged
Retail Investor holdings remained unchanged at 45.84% of holdings in Mar 2024 quarter
NO EFFECT
Against Peers
In the last 1 year, Sun Pharmaceuticals Industries Ltd has given 55.2% return, outperforming this stock by 59.8%
NO EFFECT
Against Peers
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 134.2% return, outperforming this stock by 155.1%
NO EFFECT
FII Holding Unchanged
Foreign Institutions holdings remained unchanged at 0.43% of holdings in Mar 2024 quarter
NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 53.73% of holdings in Mar 2024 quarter
NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 3 quarters, 5.87 Cr → 3.98 Cr (in ₹), with an average decrease of 16.5% per quarter
NEGATIVE IMPACT
Revenue Fall
Revenue is down for the last 3 quarters, 90.37 Cr → 69.18 Cr (in ₹), with an average decrease of 12.5% per quarter
NEGATIVE IMPACT
Price Dip
In the last 3 years, HESTERBIO stock has moved down by -20.9%